Wikidata |

Wikidata

Matches in Wikidata for { <http://www.wikidata.org/entity/Q37384289> ?p ?o ?g. }

Showing items 1 to 100 of ±150 with 100 items per page.

Q37384289 description "article científic" @default.
Q37384289 description "article scientifique" @default.
Q37384289 description "articolo scientifico" @default.
Q37384289 description "artigo científico" @default.
Q37384289 description "artículu científicu espublizáu en 2015" @default.
Q37384289 description "bilimsel makale" @default.
Q37384289 description "scientific article published on 20 July 2015" @default.
Q37384289 description "vedecký článok" @default.
Q37384289 description "vetenskaplig artikel" @default.
Q37384289 description "videnskabelig artikel" @default.
Q37384289 description "vědecký článek" @default.
Q37384289 description "wetenschappelijk artikel" @default.
Q37384289 description "wissenschaftlicher Artikel" @default.
Q37384289 description "наукова стаття, опублікована в липні 2015" @default.
Q37384289 description "научни чланак" @default.
Q37384289 description "مقالة علمية نشرت في 20 يوليو 2015" @default.
Q37384289 name "Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project" @default.
Q37384289 name "Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project" @default.
Q37384289 name "Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project" @default.
Q37384289 type Item @default.
Q37384289 label "Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project" @default.
Q37384289 label "Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project" @default.
Q37384289 label "Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project" @default.
Q37384289 prefLabel "Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project" @default.
Q37384289 prefLabel "Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project" @default.
Q37384289 prefLabel "Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project" @default.
Q37384289 P1433 Q37384289-C24E6343-06AF-47EF-A4C9-B98B21843A54 @default.
Q37384289 P1476 Q37384289-369EA865-7D85-4698-A4DB-DC77DA38E66B @default.
Q37384289 P2093 Q37384289-140FE1B3-FB3E-4972-9891-920A2D1AD969 @default.
Q37384289 P2093 Q37384289-15BD3B2E-8F45-4405-B516-0F87ED5EFAB2 @default.
Q37384289 P2093 Q37384289-1DC0770C-4BE0-4D40-AAF6-9FE0473DD741 @default.
Q37384289 P2093 Q37384289-3BEB96AE-8A95-4400-B501-67BA40B10A38 @default.
Q37384289 P2093 Q37384289-4E852945-3484-43D1-ABFA-57C30EBC90B5 @default.
Q37384289 P2093 Q37384289-92BC1282-C05B-4610-BB1F-4D84738C6A8F @default.
Q37384289 P2093 Q37384289-9474046F-A1AD-40AC-B2A4-A03D0389012A @default.
Q37384289 P2093 Q37384289-973463EE-2AC1-439C-9335-098286B8EA9E @default.
Q37384289 P2093 Q37384289-B0ACD0A3-845C-4CFB-9B70-B1A4287506D0 @default.
Q37384289 P2093 Q37384289-B2D65D80-BA92-4AB9-946F-1517DEA24186 @default.
Q37384289 P2093 Q37384289-BC537B26-8BFC-4698-A2BF-6AE3C8F40281 @default.
Q37384289 P2093 Q37384289-C12E2A1F-8B98-4104-96ED-A3D301487016 @default.
Q37384289 P2093 Q37384289-DD520330-5F6E-4333-91D7-BEEA16135A96 @default.
Q37384289 P2093 Q37384289-FFF7A3D8-DBB5-4B67-A1BF-11271C20FA50 @default.
Q37384289 P2860 Q37384289-05C74E60-F978-41B4-B11A-5434B79ED62B @default.
Q37384289 P2860 Q37384289-06794195-41EB-413E-ABE7-D48D0D525EFD @default.
Q37384289 P2860 Q37384289-0978CE7E-F8AC-49A0-B691-0FA1A168643A @default.
Q37384289 P2860 Q37384289-14573E4D-5644-4452-831D-EE2F39DA0628 @default.
Q37384289 P2860 Q37384289-239040F2-7442-4667-8ADA-039AAB7A29EA @default.
Q37384289 P2860 Q37384289-2CB534E0-1A8B-46BD-AAEC-30CE374DDF5A @default.
Q37384289 P2860 Q37384289-3771C461-A2C7-4E4F-9D5D-037FF2E17D6E @default.
Q37384289 P2860 Q37384289-3A11CE64-BB46-42FE-993C-E8E74CD3BC68 @default.
Q37384289 P2860 Q37384289-487E3E99-136F-414F-B7F9-A5D6C997C324 @default.
Q37384289 P2860 Q37384289-4B346CDD-82F0-497F-9E3C-746F454FD48B @default.
Q37384289 P2860 Q37384289-6064EF99-4CFE-48BB-AB7E-C8D6AB9F56CF @default.
Q37384289 P2860 Q37384289-6102D576-1FC7-4F2C-88EC-DD14317965AE @default.
Q37384289 P2860 Q37384289-67100D21-5918-4B57-972F-CE00F0847D67 @default.
Q37384289 P2860 Q37384289-8151DE7D-620E-4D12-A885-28A748E13FE8 @default.
Q37384289 P2860 Q37384289-87D7EA06-4E1E-4E45-9478-3BA670EEA5CD @default.
Q37384289 P2860 Q37384289-8B84086F-E866-490A-BADB-BCE2519709FA @default.
Q37384289 P2860 Q37384289-8CAE3DE7-D1FA-4AD1-A773-EF728F45C5D8 @default.
Q37384289 P2860 Q37384289-8EA65FC5-2DB9-4FD7-B2CF-D2577FDD567A @default.
Q37384289 P2860 Q37384289-9671D745-4BC4-4448-987E-822272D79981 @default.
Q37384289 P2860 Q37384289-9B64A64A-F8E4-48B5-8881-3D9D9D12480E @default.
Q37384289 P2860 Q37384289-A379CB49-6279-4989-A39C-E7D60A1724DE @default.
Q37384289 P2860 Q37384289-AA13209B-03AB-440D-B39A-DA168922117C @default.
Q37384289 P2860 Q37384289-AE16772A-4A5F-48EF-B4EE-9A9E2985225D @default.
Q37384289 P2860 Q37384289-B0D1BFD9-D891-452D-B19B-F141FFA14B2A @default.
Q37384289 P2860 Q37384289-B3DFCFA4-A5D2-4658-813C-E950DA9B3C6B @default.
Q37384289 P2860 Q37384289-B65BEBE1-AD0B-4A09-BB49-15D22E55E765 @default.
Q37384289 P2860 Q37384289-C48AF6B9-A841-458B-B051-05080A1D29C0 @default.
Q37384289 P2860 Q37384289-CA8BF84F-3A22-42DF-9960-1243A4F35E9D @default.
Q37384289 P2860 Q37384289-DC416AD2-5EC7-4171-9FF2-F883E71A7D4C @default.
Q37384289 P2860 Q37384289-E2C5B585-BF2E-4FCB-8680-EB8F4D7A63E7 @default.
Q37384289 P2860 Q37384289-FDB57FF5-4D3F-412E-AC49-63578FFF795F @default.
Q37384289 P304 Q37384289-8D8D32E5-AAD4-47AC-A670-C9508A03B192 @default.
Q37384289 P31 Q37384289-01287571-E714-4C4A-B43F-9F064F80F1C9 @default.
Q37384289 P356 Q37384289-B81D5A3A-B5BB-4417-BE21-8F3EC09922CD @default.
Q37384289 P407 Q37384289-2E0BF41C-89BB-4BCD-ABCE-11B244EE3C93 @default.
Q37384289 P433 Q37384289-09E5F662-D707-4BDB-AA09-E4AB8CF4D2F1 @default.
Q37384289 P478 Q37384289-5C2ED376-7B3D-4328-A0B2-7476D8C7E8FD @default.
Q37384289 P50 Q37384289-26EFB471-9DF1-442C-9E57-784F1E1CC3B1 @default.
Q37384289 P50 Q37384289-969C69BD-58F7-4614-9E75-3D87DF3561CD @default.
Q37384289 P50 Q37384289-F973A215-5F8E-4C87-A573-DC57DF0E0C70 @default.
Q37384289 P577 Q37384289-82323BB2-AADE-4B78-8DF8-8AC5D7395D7F @default.
Q37384289 P698 Q37384289-78CE106F-FC97-4D76-A893-2EA57BC25F9E @default.
Q37384289 P921 Q37384289-57EE2B27-CAFD-4154-9814-4860E6655A02 @default.
Q37384289 P921 Q37384289-9C20A56E-D3C9-423E-BAD3-BC9E9FC27FE5 @default.
Q37384289 P932 Q37384289-94953295-7E8D-4805-9D91-4BFEB20FC148 @default.
Q37384289 P356 JCO.2014.60.3969 @default.
Q37384289 P698 26195720 @default.
Q37384289 P1433 Q400292 @default.
Q37384289 P1476 "Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project" @default.
Q37384289 P2093 "Annie Nguyen-Lin" @default.
Q37384289 P2093 "Gary S Wood" @default.
Q37384289 P2093 "Katrin A Salva" @default.
Q37384289 P2093 "Mahkam Tavallaee" @default.
Q37384289 P2093 "Melissa Pulitzer" @default.
Q37384289 P2093 "Michael Krathen" @default.
Q37384289 P2093 "Randall Armstrong" @default.
Q37384289 P2093 "Seema Nagpal" @default.
Q37384289 P2093 "Shufeng Li" @default.